328 related articles for article (PubMed ID: 16682724)
21. The quest for improving the management of breast cancer by functional imaging: The discovery and development of 16α-[
Katzenellenbogen JA
Nucl Med Biol; 2021 Jan; 92():24-37. PubMed ID: 32229068
[TBL] [Abstract][Full Text] [Related]
22. The Application of 18 F-FES PET in Clinical Cancer Care : A Systematic Review.
Huang YT; Chen TW; Chen LY; Huang YY; Lu YS
Clin Nucl Med; 2023 Sep; 48(9):785-795. PubMed ID: 37482660
[TBL] [Abstract][Full Text] [Related]
23. 18F-Fluoroestradiol Positron Emission Tomography in Breast Cancer Patients: Systematic Review of the Literature & Meta-Analysis.
Evangelista L; Guarneri V; Conte PF
Curr Radiopharm; 2016; 9(3):244-257. PubMed ID: 27774910
[TBL] [Abstract][Full Text] [Related]
24. A Randomized Feasibility Study of
Chae SY; Kim SB; Ahn SH; Kim HO; Yoon DH; Ahn JH; Jung KH; Han S; Oh SJ; Lee SJ; Kim HJ; Son BH; Gong G; Lee HS; Moon DH
J Nucl Med; 2017 Apr; 58(4):563-568. PubMed ID: 27688475
[TBL] [Abstract][Full Text] [Related]
25. Molecular imaging to identify patients with metastatic breast cancer who benefit from endocrine treatment combined with cyclin-dependent kinase inhibition.
Boers J; Venema CM; de Vries EFJ; Glaudemans AWJM; Kwee TC; Schuuring E; Martens JWM; Elias SG; Hospers GAP; Schröder CP
Eur J Cancer; 2020 Feb; 126():11-20. PubMed ID: 31891878
[TBL] [Abstract][Full Text] [Related]
26. The Assessment of Estrogen Receptor Status and Its Intratumoral Heterogeneity in Patients With Breast Cancer by Using 18F-Fluoroestradiol PET/CT.
Yang Z; Sun Y; Xu X; Zhang Y; Zhang J; Xue J; Wang M; Yuan H; Hu S; Shi W; Zhu B; Zhang Y
Clin Nucl Med; 2017 Jun; 42(6):421-427. PubMed ID: 28221191
[TBL] [Abstract][Full Text] [Related]
27. Androgen and Estrogen Receptor Imaging in Metastatic Breast Cancer Patients as a Surrogate for Tissue Biopsies.
Venema CM; Mammatas LH; Schröder CP; van Kruchten M; Apollonio G; Glaudemans AWJM; Bongaerts AHH; Hoekstra OS; Verheul HMW; Boven E; van der Vegt B; de Vries EFJ; de Vries EGE; Boellaard R; Menke van der Houven van Oordt CW; Hospers GAP
J Nucl Med; 2017 Dec; 58(12):1906-1912. PubMed ID: 28912144
[TBL] [Abstract][Full Text] [Related]
28. Current applications of PET imaging of sex hormone receptors with a fluorinated analogue of estradiol or of testosterone.
Talbot JN; Gligorov J; Nataf V; Montravers F; Huchet V; Michaud L; Ohnona J; Balogova S; Cussenot O; Daraï E; Lotz JP; Kerrou K
Q J Nucl Med Mol Imaging; 2015 Mar; 59(1):4-17. PubMed ID: 25693420
[TBL] [Abstract][Full Text] [Related]
29. Small-animal PET of steroid hormone receptors predicts tumor response to endocrine therapy using a preclinical model of breast cancer.
Fowler AM; Chan SR; Sharp TL; Fettig NM; Zhou D; Dence CS; Carlson KE; Jeyakumar M; Katzenellenbogen JA; Schreiber RD; Welch MJ
J Nucl Med; 2012 Jul; 53(7):1119-26. PubMed ID: 22669982
[TBL] [Abstract][Full Text] [Related]
30. [18F]-fluoroestradiol quantitative PET imaging to differentiate ER+ and ERα-knockdown breast tumors in mice.
Paquette M; Ouellet R; Archambault M; Croteau É; Lecomte R; Bénard F
Nucl Med Biol; 2012 Jan; 39(1):57-64. PubMed ID: 22079037
[TBL] [Abstract][Full Text] [Related]
31. Clinical production, stability studies and PET imaging with 16-alpha-[18F]fluoroestradiol ([18F]FES) in ER positive breast cancer patients.
Kumar P; Mercer J; Doerkson C; Tonkin K; McEwan AJ
J Pharm Pharm Sci; 2007; 10(2):256s-265s. PubMed ID: 17718929
[TBL] [Abstract][Full Text] [Related]
32. The preliminary study of 16α-[18F]fluoroestradiol PET/CT in assisting the individualized treatment decisions of breast cancer patients.
Sun Y; Yang Z; Zhang Y; Xue J; Wang M; Shi W; Zhu B; Hu S; Yao Z; Pan H; Zhang Y
PLoS One; 2015; 10(1):e0116341. PubMed ID: 25617853
[TBL] [Abstract][Full Text] [Related]
33. A phase 2 study of 16α-[18F]-fluoro-17β-estradiol positron emission tomography (FES-PET) as a marker of hormone sensitivity in metastatic breast cancer (MBC).
Peterson LM; Kurland BF; Schubert EK; Link JM; Gadi VK; Specht JM; Eary JF; Porter P; Shankar LK; Mankoff DA; Linden HM
Mol Imaging Biol; 2014 Jun; 16(3):431-40. PubMed ID: 24170452
[TBL] [Abstract][Full Text] [Related]
34. Diffuse bilateral
Phillips EF; Karak PK
J Med Imaging Radiat Sci; 2023 Dec; 54(4):726-731. PubMed ID: 37620179
[TBL] [Abstract][Full Text] [Related]
35. Evaluation of tumour heterogeneity by
Liu C; Hu S; Xu X; Zhang Y; Wang B; Song S; Yang Z
Breast Cancer Res; 2022 Aug; 24(1):57. PubMed ID: 36028895
[TBL] [Abstract][Full Text] [Related]
36. Positron emission tomography of tumour [(18)F]fluoroestradiol uptake in patients with acquired hormone-resistant metastatic breast cancer prior to oestradiol therapy.
van Kruchten M; Glaudemans AWJM; de Vries EFJ; Schröder CP; de Vries EGE; Hospers GAP
Eur J Nucl Med Mol Imaging; 2015 Oct; 42(11):1674-1681. PubMed ID: 26091705
[TBL] [Abstract][Full Text] [Related]
37. The development of estrogen and progestin radiopharmaceuticals for imaging breast cancer.
Katzenellenbogen JA; Welch MJ; Dehdashti F
Anticancer Res; 1997; 17(3B):1573-6. PubMed ID: 9179196
[TBL] [Abstract][Full Text] [Related]
38. 18F-Fluoroestradiol.
Sundararajan L; Linden HM; Link JM; Krohn KA; Mankoff DA
Semin Nucl Med; 2007 Nov; 37(6):470-6. PubMed ID: 17920354
[TBL] [Abstract][Full Text] [Related]
39. 18F-fluoromisonidazole PET/CT: a potential tool for predicting primary endocrine therapy resistance in breast cancer.
Cheng J; Lei L; Xu J; Sun Y; Zhang Y; Wang X; Pan L; Shao Z; Zhang Y; Liu G
J Nucl Med; 2013 Mar; 54(3):333-40. PubMed ID: 23401605
[TBL] [Abstract][Full Text] [Related]
40. Lower-dose vs high-dose oral estradiol therapy of hormone receptor-positive, aromatase inhibitor-resistant advanced breast cancer: a phase 2 randomized study.
Ellis MJ; Gao F; Dehdashti F; Jeffe DB; Marcom PK; Carey LA; Dickler MN; Silverman P; Fleming GF; Kommareddy A; Jamalabadi-Majidi S; Crowder R; Siegel BA
JAMA; 2009 Aug; 302(7):774-80. PubMed ID: 19690310
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]